We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
May be it was just a shake, to buy now 4.07
Totally agree - this is nuts response from market. Large player in diagnostics sector - potential to see returns much quicker than if this was clinical antibody too as they’ll not need to go through trials etc! Only can be seen as positive!
Can only get a quote to buy on 10,000 shares no more, still at 4p for the 10,000
LOTM
Lotm couldnt agree more,a major with deep pockets will do the research,spend there money and what ever they come up with and use we get the royalty without spending a penny,sounds like a great deal for us,if they find and use 50 new drugs then thats 50 revenue streams from the royalties,thats money in the bank,, the rns has already said as much in the words the payment is not important,material/ and fab can still see to other companys and still do its own research,its like a big ,wise older brother helping out,and wealthy enough to get things done quickly,something we cant do with a 4 m mcap. at the moment,watch this space....
So needs volume, now gone NT to buy following that 125,000 trade.
Hmm are MM's playing silly games ?
LOTM
4/4.20 to buy at 4 now, could drop further
Clearly its not otherwise the share price wouldn't now be be down on the day & people able to buy at 4p a share now.
Its going to be interesting to see any delayed trades that occurred in the 1st 30 mins or so of trading.
Clearly a lot more turnover is required to clear the stock overhang that's in the background.
Need to find some new investors.
LOTM
The upside from this level is huge, great new today and I expect plenty of news flow coming through in the coming weeks /months.
4m mkcap is a giveaway.
Value will start to show soon enough,
Atb.
Only £4.1m after that RNS. Much further to go IMO
Hi chrishutch,
Was that the news you were expecting to see or is there more in the immediate pipeline ?
Thanks
LOTM
Hmm looks like the market is not impressed with the news, possibly the lack of an upfront payment or the lack of news about what this might be worth in the future.
Looks like the CEO is going to have to do some PR to give investors some form of clue as to the long term benefits of this deal.
Not many buyers thus far which is clearly disappointing & it clearly looks like there is a big seller out there, possibly left over from the placing.
GLA
LOTM
“ a leading global provider of antibodies for use in research and diagnostics ”
You don't grant someone Exclusivity straight away on a brand new product with little upfront money, unless they are a major player & likely to be paying you lots of royalties in the future.
LOTM
Thunderbirds are Go at F.A.B
GLA
LOTM
Nice RNS, do we know how much is this contract worth , going in right direction
Reading between the lines here but it also sounds like less dependence on using animals for testing and research ?
Which is great from an ethical and animal welfare point of view .
I wonder who the customer is ?
Amy ideas ?
OptiPhageTM, a phage display based version of the same DNA library. OptiPhageTM uses the same DNA sequences as OptiMAL® but packages them into a more commonly used Phage display format. Only smaller antibody fragments can be screened in this way, compared to whole antibodies via OptiMAL®, but it can be run at a lower price point for the customer. The Directors believe that the provision of OptiPhageTM provides the Company with an ability to protect the premium pricing of the OptiMAL® programme whilst meeting budgetary constraints of its customers. It may also be the platform of choice for those wanting antibody fragments as their end product; and
Excellent news,
This technology is worth an absolute fortune for the company,
What a great turnaround,,
Exciting times we are at the start of a huge recovery for
This company
Great news they’ve been able to commercialise this new technology platform with great potential for royalties on antibodies developed and sold.
I think we will see an attack of that higher over the next few sessions
Ready for a good recovery as FAB has diversified into so many areas of interest and with huge potential also.
I also like the fact that we’ve move into the veterinary sector where there’s an amazing opportunity to increase revenue massively.
Also to be partners with the NCI is a huge milestone for the company and should bring FAB into the limelight’
Just about to begin here.
Mitchell Ho, Ph.D., Deputy Chief, Laboratory of Molecular Biology and Director of the Antibody Engineering Program, Center for Cancer Research, NCI commented: " NCI will test the OptiMAL (R) platform for the discovery of novel antibodies to cancer targets and also SARS-CoV-2. We have a particular interest in Mammalian Cell Display as a discovery engine and look forward to using this in NCI."
Richard Buick, CSO of Fusion, commented: " The expertise and experience of Dr. Ho and his colleagues make NCI an ideal partner for validation of the Optimal (R) library and mammalian cell display technology. I look forward to the collaboration and working closely with the National Cancer Institute."
Can’t say much. But if what I hearing is true, then it could be a great time to be involved.
You’ve still not given any more on these rumours…
Yep